Introduction
Circadian (daily) rhythms regulate gene-expression patterns, cellular activities, and behavioral phenomena [1] . In mammals, a circadian oscillator in the suprachiasmatic nuclei (SCN) of the hypothalamus appears to be a central pacemaker that coordinates circadian oscillators in peripheral tissues and cells, including liver, lung, kidney, muscle, cornea, and fibroblasts [2] [3] [4] [5] [6] [7] . A network of evidence supports a model for the mammalian clockwork that proposes autoregulatory transcriptional and translational feedback loops (TTFLs) of key ''clock proteins'' that are rhythmically abundant and that interact with one another to feed back upon the transcriptional activity of their respective genes [8] [9] [10] [11] . In mammals, positive transcriptional ''drive'' is provided by a heterodimer of the bHLH-PAS factors, BMAL1 and CLOCK (and/or NPAS2 [12] ), and this heterodimer activates transcription at E box enhancers [13] . Negative feedback in the system is primarily accomplished by Period (especially PER1 and PER2) and Cryptochrome (CRY1 and CRY2) gene products that translocate to the nucleus and repress the transcription of their own genes [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Although an important role for posttranslational modification of key mammalian clock proteins is recognized [24] [25] [26] , the rhythmic expression of mRNAs and proteins encoded by key clock genes has led to the understandable conclusion that these rhythmic expression patterns are essential [8, 9, 14-16, 19, 20, 27-29] . However, this is obviously not necessarily true; an essential gene product might have a rhythmic expression pattern that is not inevitably functional. For example, in plants, LhcII transcript levels and translational rates exhibit daily or circadian oscillations, but these rhythmic patterns are not converted into downstream patterns of LHCII protein abundance [30, 31] .
The TTFL model can be used to predict whether specific components need to oscillate [8-11, 32, 33] . Cycling of the positive components (especially CLOCK and BMAL1) appears to be unnecessary for circadian precession [34] [35] [36] , and consequently, testing the TTFL's prediction of rhythmically expressed factors has focused upon the negative limb components PER1/2 and CRY1/2. Consistent with the TTFL model, constitutive overexpression of mCry1 mRNA in mammalian cells has been reported to enhance damping [37] . In addition to constitutive-overexpression studies, however, an important support for the TTFL model in other organisms has been perturbation analyses where experimental expression of clock proteins as pulses or steps was used to determine whether the oscillator is reset in a phase-dependent fashion. For example, in the cases of Drosophila, Neurospora, and cyanobacteria, inducible promoters that rapidly turn on or off were used to drive expression of clock genes, thereby eliciting phase setting or phase shifting [38] [39] [40] [41] . This approach has not yet been reported in mammals for pulse or step perturbations, presumably because of the lack of an inducible promoter system in which clock-protein expression can be turned on or off rapidly [42, 43] .
A better methodology for perturbation analyses is needed to provide definitive tests of the predictions of the TTFL model in mammalian cells. An alternative approach that has not yet been applied to the study of circadian rhythms is to fuse a protein transduction domain (PTD) to a clock protein and transduce it directly across the cell membrane. This novel method would allow the rapid introduction of a clock protein into cells without the complications of transcriptional or posttranscriptional regulation. If the turnover rate of the modified clock protein is sufficiently high, this technology would permit the administration of pulses of the clock protein as well. In other applications, PTDs have been used to import functional peptides and proteins into multiple cell types so as to probe signal transduction pathways, to introduce recombinases, to alter cell-division kinetics, and to act for other purposes [44] [45] [46] [47] [48] [49] . The wide range of cell types and the ease of translocation across the plasma membrane overcome the limitations of other, more invasive, methods of introducing proteins directly into cells such as microinjection or membrane-permeabilizing reagents [44, 49, 50] . By using this technology to test predictions of the circadian TTFL model in mammalian fibroblasts, we found that cell-permeant CRY proteins (CP-CRYs) (1) can rescue the arhythmia of Cry1
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2/2 mammalian fibroblasts, (2) can phase shift the fibroblast oscillator, (3) can upregulate BMAL1 expression levels, and (4) can demonstrate that cycling of CRY1, CRY2, and BMAL1 proteins is not necessary for clock function in mammalian fibroblasts. Therefore, in contrast to the current TTFL model of the mammalian clockwork, our results question whether rhythmicity in the abundances of mCRY1 and mCRY2 is essential for operation of the mammalian circadian oscillator.
Results
Translocation of Cell-Permeable Mouse CRY1 and CRY2 into Mammalian Cells Cell-permeant-protein technology has used PTDs that are composed of either (1) positively charged residues such as the TAT peptide [44] or a series of arginine residues [45] or (2) hydrophobic residues [46] [47] [48] . We chose the latter type of PTD for making cell-permeant mouse CRY1 and CRY2 (CP-CRY1 and CP-CRY2), as shown in Figure 1A . Recombinant CP-CRY1 and CP-CRY2 fusion proteins have a C-terminal hydrophobic sequence, AAVLLPVLLAAP from Kaposi FGF-4 (called the MTS for ''membrane-transduction sequence''), which can mediate uptake of proteins directly through membranes [46] , and a N-terminal NLS (nuclear localization signal) from simian virus 40 large T antigen to ensure the translocation of the protein into the nucleus (and the NLS has additionally been found in some cases to aid the translocation across the plasma membrane as well [47] ). A His6 tag was included for protein purification.
The CP-CRYs can be expressed as soluble proteins in E. coli and purified ( Figure 1B ). For testing the uptake of CP-proteins in cultured cells, fluorescein-labeled CP-proteins were incubated with Rat-1 fibroblasts and HEK293 cells. CP-CRYs, CP-mutCRY1, and CP-CRE are taken up into Rat-1 fibroblasts ( Figure 1C ) and into HEK293 cells (data not shown). There appears to be some aggregation of CP-CRY1, CP-mutCRY1, and CP-CRE in the cells that might have cytoplasmic loci; these might be analogous to the cytoplasmic loci found for PER and TIM in Drosophila [51] , whereas CP-CRY2 appears to be more homogeneously distributed. In all cases, however, there appears to be nonaggregated CP proteins throughout the cytoplasm and nuclei. As has been found for CP proteins in other studies, the transduction efficiency of CP-CRYs into fibroblasts is approximately 95%. Uptake of extracellular CP-CRYs can also be detected by immunoblotting of treated cells with CRY1 and CRY2 polyclonal IgG antibodies. When CP-CRY1 or CP-CRY2 is present continuously in the medium, the intracellular levels of CP-CRY1 or CP-CRY2 are present at high levels that do not fluctuate with a circadian period ( Figure S1 in the Supplemental Data available online).
Repression of BMAL1/CLOCK-Mediated Transcription by CP-CRYs
A standard assay for CRY activity is the inhibition of BMAL1/CLOCK-dependent transactivation of E boxcontaining promoters [19, 52] . In transient-transfection assays, cotransfected hamster Bmal1 (haBmal1) and mouse Clock (mClock) can activate the E box-containing PK2 promoter (P PK2 ; see [53] ), and this activation can be significantly repressed by cotransfected CPmCry1 that is intracellularly expressed under the control of P CMV (Figures 2A and 2B ). It also can be suppressed by the extracellular addition of CP-CRYs (Figures 2A  and 2B ). Repression by either intracellularly expressed CP-CRY1 or by extracellularly applied CP-CRY1 was dose dependent ( Figure 2B and Figure S2 ). We used a cell-permeant version of Cre Recombinase (CP-CRE) that has previously been shown to translocate into cells and confer intracellular loxP-specific recombination activity [47] as a control protein for our studies. CP-CRE uses the same MTS and NLS as our CP proteins, and it translocates into fibroblasts ( Figure 1C 4 ), but it does not repress P PK2 ::Fluc activity when it is added to the extracellular medium ( Figure 2A ). As another control, a mutant CP-CRY1 (CP-mutCRY1) was constructed, on the basis of a study showing that mutation of aspartate residue 387 of mouse CRY1 to alanine (D387A) results in a reduced (but not eliminated) inhibition of E box-containing promoters [54] . In transient-transfection assays, both intracellularly expressed and extracellularly applied CP-mutCRY1 showed significantly less inhibition than CP-CRY1 at low dosages. As found in the original publication [54] , however, the D387A mutant is able to inhibit E box promoters at high dosage ( Figure 2B and Figure S2 ). The data in Figure 2 show the suppressive action on P PK2 ::Fluc activity, but essentially identical results were obtained for the repression of P mPer1 ::Fluc activity by CP-CRY (data not shown).
CP-CRY1 and CP-CRY2 Can Rescue Circadian Properties in mCry1
2/2 Mouse Fibroblasts In fibroblasts and SCN slices derived from mice in which the mCry1 and mCry2 genes have been knocked out (mCry1
), mPer1 and mPer2 RNA levels are arrhythmic and expressed at middle to high values compared with wild-type mouse fibroblasts and SCN slices [5, 18] . In fibroblasts derived from mCry1
double-knockout mice [55] , we found that PER1 levels did not oscillate and were higher than those in fibroblasts derived from wild-type mice ( Figures 3A and 3B ). After treatment with CP-CRY1 + CP-CRY2, the PER1 level in knockout fibroblasts was reduced from the high levels that are diagnostic of mCry1
2/2 fibroblasts to levels similar to that of the wild-type fibroblasts ( Figures 3A and 3B ). This effect is probably mediated by the suppressive activity of cryptochromes on the BMAL1/CLOCK complex [19] .
CP-CRY1 and CP-CRY2 can also rescue the rhythmicity of mCry1
2/2 fibroblasts. We transfected wild-type and mCry1
2/2 fibroblasts with a P Bmal1 ::Fluc luminescence reporter plasmid by nucleofection. Wild-type mouse fibroblasts express a circadian rhythm of luminescence, whereas mCry1
fibroblasts are arrhythmic ( Figure 3C ). However, mCry1 2/2 mCry2 2/2 fibroblasts treated with CP-CRY1 + CP-CRY2 recovered rhythmicity. The data depicted in Figure 3C are detrended data because the luminescence rhythms of these mouse fibroblasts-even of the wild-type fibroblasts-are consistently less robust than that of the Rat-1 fibroblasts shown below. These data indicate that CP-CRY1 and CP-CRY2 are functionally active in vivo.
CP-CRY1 and CP-CRY2 Induce BMAL1 but Not CLOCK Expression Coordination between the positive (BMAL1 and CLOCK/ NPAS2) and negative (PER1/2 and CRY1/2) limbs of the mammalian TTFL is facilitated by the orphan nuclear receptor REV-ERBa-the BMAL1/CLOCK heterodimer activates REV-ERBa, which then represses further Bmal1 transcription [34, 56] . CRY proteins repress the activity of BMAL1/CLOCK, thereby repressing REVERBa expression [34] . Therefore, because CRY proteins repress the repressor of BMAL1 (i.e., REV-ERBa), CRY proteins activate Bmal1 transcription [57] . Moreover, CRY1 binds to the C terminus of BMAL1 and protects BMAL1 from degradation [36] . Therefore, CP-CRY proteins could enhance BMAL1 levels both by transcriptional activation of P bmal1 activity and by inhibition of BMAL1 degradation. On the basis of these predictions, we confirmed the functional activity of CP-CRY1 and CP-CRY2. With conditions in which control endogenous levels of BMAL1 are undetectable by immunoblotting (''PBS'' in Figure 4A ), CP-CRE does not elevate BMAL1, but both CP-CRY1 and CP-CRY2 dramatically upregulate BMAL1 protein levels within 30 min after treatment with the CP proteins ( Figures 4A and 4B ). This upregulation is at least 10-to 20-fold and is HEK293 cells were transfected with haBmal1, mouse Clock, and an E box-containing promoter P PK2 -driven luciferase reporter (P PK2 ::luc). (A) Intracellularly expressed CRY (P CMV ::Cry1) and extracellularly applied CP-CRYs on P PK2 activity were evaluated with a luciferase assay of PK2 promoter activity. The concentrations of CP-CRY1, CP-CRY2, and CP-CRE proteins were 250 nM. (B) Both transfected P CMV ::Cry1 and extracellularly applied CP-CRY can inhibit P PK2 activity. Extracellularly applied CP-CRY1 and CP-mutCRY1 both inhibit P PK2 activity in a dose-dependent fashion, but CP-mutCRY1 is less effective than CP-CRY1. Protein concentrations are as follows: +, 5 nM; ++, 50 nM; and +++, 250 nM. The plotted values are mean 6SD of three replicates. Asterisks indicate significant differences from haBmal1/ mClock controls at the p < 0.01 level (Student's t test).
constitutive ( Figure S3 ). This effect is likely to be mediated (at least partially) by induction of P Bmal1 because P Bmal1 activity is stimulated acutely by treatment with CP-CRY proteins in both Rat-1 and mCry1
fibroblasts ( Figure S4 ). Pulse treatments of CP-CRY1 or CP-CRY2 for 3 hr or 6 hr upregulate BMAL1 for only the time of exposure to these proteins. After wash out of CP-CRY1, the upregulated BMAL1 disappears within 1 hr ( Figure 4B ). As was true for the transient-transfection assay of P PK2 activity (Figure 2 ), CP-mutCRY1 (D387A) is less active than CP-CRY1 in the induction of BMAL1; i.e., a low concentration (5 nM) of CP-mutCRY1 is less effective, whereas higher concentrations of CPmutCRY1 (25 and 100 nM) appear to be equivalent to those of CP-CRY1 ( Figure 4C ). Finally, CP-CRYs do not nonspecifically induce all proteins in Rat-1 fibroblasts (or even all core clock proteins) because neither CP-CRY1 nor CP-CRY2 had a significant effect on CLOCK protein levels ( Figure S5 ). The data of Figure 4A show clearly that the intracellular activity of CP-CRY is not rhythmic, as judged by the activation of BMAL1 levels. Apparently, extracellular CP-CRY is continuously entering the cells, where it is inactivated or degraded relatively rapidly as judged by the rapid decline in BMAL1 levels when extracellular CP-CRY is removed ( Figure 4B ).
Phase Shift of the Rhythm in Rat-1 Fibroblasts by CP-CRYs As judged by the upregulation of BMAL1 levels ( Figure 4 ) and P Bmal1 activity ( Figure S4 ), the CP-CRY proteins are functionally active soon after they are administered in the extracellular medium. This makes them ideal for perturbation experiments. We used Rat-1 fibroblasts that have been stably transfected with a P Per2 ::Fluc reporter because they exhibit robust circadian oscillations of luminescence for several days after synchronization by 10 mM forskolin. The addition of either CP-CRY1 or CP-CRY2 (''step'' treatments, i.e., continuous treatments) can phase shift the P Per2 ::Fluc reporter rhythm in a phase-dependent manner, whereas CP-CRE and PBS have no effect.
Step treatments of CP-CRY1 or CP-CRY2 can elicit phase shifts up to 3 hr (either advances or delays, depending upon the phase of the treatment onset; Figure 5 ). At low concentrations (5 nM), CP-mutCRY1 has less (or no) phase-resetting activity effect on the Rat-1 rhythms ( Figure 5B), and this finding is consistent with its reduced efficacy in the transient-transfection assay ( Figure 2B ). When the data for CP-CRY1 and CP-CRY2 are plotted as phaseresponse curves (PRCs), the resetting effects are clearly phase dependent ( Figure 5D ) and stable ( Figure 5C ). The phase position of PRCs for CP-CRY1 versus CP-CRY2 is similar, consistent with the similar phasing of CRY1 and CRY2 expression [28] , but the PRC for CP-CRY2 may be slightly delayed relative to that of CP-CRY1 ( Figure 5D ). The phase resetting and BMAL1 activation we observe with CP-CRY1 and CP-CRY2 is likely to be due to a CRY-specific action and not due to a nonspecific increase of membrane permeability. This was demonstrated by the observation that none of the CP proteins stimulated a Ca 2+ influx into fibroblasts under conditions in which ATP does elicit a Ca 2+ flux ( Figure S6 ). There were two surprises in the data shown in Figure 5 . First, the continuous treatments with CP-CRY1 or CP-CRY2 caused phase resetting but did not cause a period change ( Figure 5C ). Second, there was no acute repressive effect on P Per2 activity at the time of CP-CRY addition as would have been predicted by the data derived from the transient-transfection assay (Figure 2 and  [19] ). In fact, at most phases when CP-CRY1 or CP-CRY2 was added, the acute effect on P Per2 activity was either stimulatory (as shown in Figure 5A ) or had no effect. (Also note the acute stimulation of P Bmal1 in Figure S4 .) This discrepancy will be addressed in the Discussion. CRY1, CRY2, and BMAL1 Cycling Is Not Required for the Circadian Oscillations of Rat-1 Fibroblasts Ueda and coworkers [37] have reported that intracellular overexpression of mCry1 from the P CMV promoter inhibits rhythmicity in transiently transfected Rat-1 fibroblasts. CP-CRY1 and CP-CRY2 afford an alternative approach to address the issue of CRY suppression of rhythmicity. As shown in Figure 4A , the addition of either CP-CRY1 or CP-CRY2 results in a 103 to 203 BMAL1 overexpression that persists as long as the CP protein is present in the extracellular medium. Although the BMAL1 level is not clamped at an absolutely constant level, it is clamped at a very high level and its fluctuations are not circadian. Nevertheless, Figure 6 shows that treatment with either CP-CRY1 or CP-CRY2 or both does not suppress the circadian clock, as monitored by rhythmicity of the P Per2 ::Fluc reporter in Rat-1 cells. Table 1 summarizes the data from four separate experiments that show the addition of CP-CRY1 or CP-CRY2, or both, does not significantly enhance the damping rate of the rhythm.
Discussion
Manipulating Intracellular Clock-Protein Concentrations with Cell-Permeant Proteins Direct manipulation of clock-protein abundances in Neurospora, Drosophila, and cyanobacteria has been accomplished by use of inducible promoters to drive expression of clock genes to elicit phase setting or phase shifting [38] [39] [40] [41] . On the other hand, rapid transitions of the abundance of clock proteins have not been reported for mammalian studies involving either inducible promoter systems or transfected DNA plasmids [37, [58] [59] [60] . For example, a study that applied a doxycycline-responsive promoter system to drive mPER2 expression in mammalian fibroblasts used the system only for constitutive on or off expression rather than as pulses or steps [58] . Moreover, even when mPer2 mRNA transcription is constitutively driven in mammalian cells, posttranscriptional processes confer rhythmicity on the protein's abundance [59, 60] , as had already been reported for Drosophila PER [61] . Another approach has been to transiently transfect mammalian cells with a construct driving clock-gene expression from a constitutive promoter; an investigation using that strategy reported that constant expression of mCry1 abolished circadian rhythmicity [37] . We have taken a different approach toward manipulating the intracellular levels of clock proteins. Our cell-permeantprotein strategy enabled the perturbation of CRY levels without the complications of transcriptional or translational regulation. Moreover, the intracellular activity of CP-clock proteins can be rapidly turned on or off; in the case of our studies, we have used the induction of BMAL1 protein as a gauge of the intracellular activity of the extracellularly applied CP-CRYs ( Figure 4A ). BMAL1 levels changed rapidly in response to the addition or removal of extracellular CP-CRYs ( Figure 4B ). This rapid response demonstrates the usefulness of using CP-proteins for perturbation analyses of circadian clocks.
We found that step treatments reset phase and that a PRC composed of both advance and delay shifts can be obtained from these stimuli. These step treatments of CP-CRYs do not cause a significant change in period, nor do they suppress the amplitude of the rhythm (see next section). Surprisingly, even though CP-CRYs enhance P Bmal1 activity as expected (Figure S4 ; see [34, 57] ), CP-CRYs do not acutely repress P mPer2 activity in cells in which the reporter's luminescence is continuously monitored, whereas in transiently transfected HEK293 cells, CP-CRYs repressed BMAL1/ CLOCK activation of the E box-containing promoters P PK2 ( Figure 2 ) and P mPer1 (not shown). These differences in the acute repression of P Per activity may stem from the fact that BMAL1 and CLOCK are usually overexpressed from plasmids in the standard transienttransfection assay (as shown in Figure 2 and Figure S2) , and therefore the stoichiometries of transcriptional factors are different from the case of our stably transfected Rat-1 reporter cells that have only chromosomal copies of Bmal1 and Clock.
Does the Clock Require Cyclic Expression of Clock Proteins?
The current model of the mammalian clockwork is based on a TTFL model that posits central clock proteins being transcribed and translated rhythmically in an ''autoregulatory'' negative-feedback loop. A crucial prediction of the model is that there will be at least one essential clock protein whose oscillation is necessary. The TTFL model has been mathematically modeled with realistic values for state variables and parameters assigned to the known components of this clockwork [32, 33] . At the current time, essential components of the mammalian clockwork include PER1/2, CRY1/2, BMAL1, and CLOCK/NPAS2. For which of these clock proteins can it be shown that rhythmic abundance is indispensable? Rhythmicity of the positive elements CLOCK and BMAL1 does not appear to be necessary [34] [35] [36] . CLOCK is not rhythmically expressed in Rat-1 fibroblasts ( Figure 4D ), although it might exhibit low-amplitude oscillations in some mammalian tissues as inferred from the low-amplitude mRNA-abundance rhythms seen in some peripheral tissues [62] . BMAL1 is rhythmically expressed, but several studies have shown that constitutive expression of BMAL1 does not interfere with normal clock operation in animals [34, 35] or in cell cultures [36] . We also find by using our cell-permeant-clock-protein approach that the constitutive overexpression of BMAL1 evoked by treatment with CP-CRY1 or CP-CRY2, or both, does not significantly affect the circadian oscillator in Rat-1 cells (Figures 4A and 6) .
On the other hand, rhythmicity of the levels of the essential negative elements PER1/2 and CRY1/2 has been thought to be indispensable. Ueda and coworkers [37] report that the overexpression of mCry1 from a transfected plasmid abolishes rhythmicity. By using cell-permeant CRY proteins, we obtained a different result. CP-CRY1 or CP-CRY2 treatment, or both, causes a large and constitutive increase of BMAL1 levels in Rat-1 fibroblasts (Figure 4) , indicating continued intracellular activity of the cell-permeant CRY proteins. However, this treatment does not abolish (or even significantly dampen) the oscillator as judged by the rhythm of P Per2 activity ( Figure 6 and Table 1 ). Our results are not consistent with the conclusions of Ueda and coworkers. However, our methods are different from their methods; by using cell-permeant clock proteins, we directly perturb the cellular levels of CRY proteins, whereas the intracellular overexpression methodology of Ueda and coworkers implicates additional layers of transcriptional and posttranscriptional regulation [37] . Moreover, by assaying the activation of BMAL1 by CPCRYs, we could ascertain the relative dose of active cryptochrome, whereas in the study of Ueda and coworkers, there was no way of knowing how much the CRY levels have been elevated.
Another important methodological distinction that might explain the discrepancy between our results and those of Ueda and coworkers [37] is that different P Per2 elements were used in the luminescence reporters: Our P Per2 region was larger (21670 to +53; see [7] ), whereas their P Per2 region was considerably smaller (2219 to +76; see [37] ). Therefore, because our P Per2 :: Fluc reporter includes more potential regulatory sites, it is probable that our results reflect a broader spectrum of regulatory inputs to P Per2 activity. Finally, it might be argued that the cell-permeant recombinant proteins used in this study lack CRY's usual cofactors [21, 22] and therefore behave differently from endogenously produced CRY that might contain a full complement of cofactors. However, recombinant CP-CRY represses P PK2 activity in the transcriptional assay (Figure 2 ), indicating that it is functionally active; moreover, spectral measurements of CP-CRY confirm that it has incorporated the cofactors FAD and pterin ( Figure S7 ).
Broader Implications
Do our results topple the TTFL model? Certainly not. Rhythmic abundance(s) of the essential clock proteins PER1/2 may still be required for a functional clockwork. A number of studies support the necessity of PER1 or PER2 rhythms, or both, in animals [63, 64] or in cell cultures [58] [59] [60] . Our results indicate that rhythmicity of the essential clock proteins CRY1/2 is not necessary and focus attention upon PER1/2 as the bastion upon which rhythmic transcription and translation could be founded. Nevertheless, it might be prudent to consider whether it is time for a major tune-up of the TTFL model for the mammalian clockwork. Such a re-evaluation has occurred in the case of the circadian-clock mechanism in cyanobacteria, where the same kind of evidence that supports a TTFL in the mammalian clockwork was previously used to support a TTFL mechanism in cyanobacteria [39, 41, 65] . Recent studies have shown that a TTFL mechanism is not necessary in cyanobacteria under some conditions (e.g., DD; see [65] ). Moreover, three cyanobacterial clock proteins purified and mixed in a test tube can reconstitute a circadian oscillation in vitro [66, 67] . This result unequivocally demonstrates that a posttranslational circadian oscillator can operate under some conditions without a negative-feedback transcriptional and translational loop, and this insight could be relevant to the case of mammalian clocks.
Is it possible that-by analogy with the cyanobacterial system-there is a core mammalian clockwork that is purely posttranslational? This possibility cannot be ignored, and it is possible that our results with CP-CRY proteins intimate that underlying posttranslational clock. An intriguing final speculation upon the discrepancy between our results and those of Ueda and coworkers [37] is that the intracellular expression of CRY1 in their study has the effect of continuously flooding the cells with newly synthesized protein that is not posttranslationally modified, whereas our CP-CRYs have already incorporated the FAD/pterin cofactors ( Figure S7 ) and may be otherwise posttranslationally modified. Perhaps if a posttranslational oscillator is the core mammalian clockwork, the introduction of posttranslationally modified CRY (as with CP-CRYs) may perturb the core oscillator less than the new synthesis of unmodified CRY proteins. It may be in the fullness of time that this era of re-evaluation will lead to minor alterations of our understanding of the mammalian clockwork and that the TTFL model will emerge triumphant. On the other hand, this time of re-evaluation may lead to a very different comprehension of the mammalian clock mechanism.
Experimental Procedures
Expression and Purification of Cell-Permeant CRY1 and CRY2 Proteins NLS-mCry1-MTS and NLS-mCry2-MTS were constructed by amplification of mouse Cry1 (NM_007771) and mouse Cry2 (NM_009963) sequences with primers A and B for mCry1 and primers C and D for mCry2 (see below) (templates were a gift from Dr. Steven Reppert). The PCR products were cloned into the expression vector pET28a+ (Novagen). The resulting constructs were used to express NLS-mCRY1-MTS (=CP-mCRY1) and NLS-mCRY2-MTS (=CP-mCRY2) fusion proteins that were purified by metal affinity chromatography as described in the Supplemental Data. As a control, a mutant NLS-CRY1-MTS (CP-mutCRY1 with D387A) was constructed on the basis of the sequence described in [54] . For the transient-transfection assay of P PK2 activity, the following constructs were made in pcDNA3.1: pP CMV ::NLS-mCry1-MTS, pP CMV ::NLS-mCry2-MTS, and pP CMV ::NLS-mutCry1-MTS. CP-CRY2, CP-mutCRY1, and CP-CRE were added to cultured HEK293 cells and Rat-1 fibroblasts for 30 min (''CP-CRE'' = CPCre recombinase; see [47, 48] ). Then, cells were washed with PBS and treated with proteinase K (5 mg/ml) for 10 min at 37 C. Proteinase K is a broad spectrum protease that was used for eliminating nonspecific adherence of proteins to the cell surface, thereby distinguishing between CP proteins translocated into cells from those sticking to the outside of the cell. Cells were then washed three times with PBS and observed with a fluorescence microscope (Axioscope; Zeiss) with a CCD camera (Princeton Instruments).
Transient-Transfection Assay HEK293 cells were grown at 37 C in DMEM (11965-092, GIBCO/Invitrogen) supplemented with 10% FBS, 50 units/ml penicillin, and 50 mg/ml streptomycin. Approximately 2 3 10 4 cells were seeded in each well in a 96-well plate 1 day before transfection. When the cells reached 90%-95% confluency, they were transfected with Lipofectamine 2000 (Invitrogen) with various combinations of the following constructs (all in pcDNA3.1): 100 ng pP CMV ::mClock, 100 ng pP CMV ::haBmal1, 0.5 ng pP CMV ::Rluc, and/or 100 ng pP PK2 ::Fluc. Twenty-four hours after transfection, 250 nM CP-CRY1, 250 nM CP-CRY2, 250 nM CP-mutCRY1, and 250 nM CP-CRE were added to the medium and incubated for 4 hr. Then, the cells were lysed with passive lysis buffer and firefly luciferase (Fluc), and Renilla (Rluc) luciferase activities were assayed with the Dual-Luciferase Assay Kit (Promega).
Mouse Fibroblasts Wild-type and Cry1 2/2 Cry2 2/2 double knockout mouse fibroblasts (provided by Dr. Aziz Sancar) were cultured at 37 C in DMEM (11965-092, GIBCO/Invitrogen) supplemented with 10% FBS, 50 units/ml penicillin, and 50 mg/ml streptomycin. For testing the effect of CP-CRY treatment on PER1 levels, 1 3 10 6 mouse fibroblast cells were seeded in 35 mm dishes 2 days before treatment with CP proteins. Then, both wild-type and knockout fibroblasts were treated with forskolin (10 mM) for 2 hr to synchronize the cells in the population (this incubation included CP proteins for the samples to be treated). After this synchronization treatment, the cells were washed with DMEM and resuspended in DMEM without or with 0.1 mM CP-CRY1 + 0.1 mM CP-CRY2. Every 4 hr thereafter, cells were washed with cold PBS twice and lysed. Proteins in the lysates were separated by SDS-PAGE (in 7.5% acrylamide gels) and then transferred to nitrocellulose membranes for immunoblotting. AntimPER1 polyclonal IgG (#516045, Calbiochem) was used for detection of the PER1 levels.
For ''rescue'' of rhythmicity in Cry1
Cry2 2/2 double-knockout mouse fibroblasts, 1 3 10 6 cells were seeded in 35 mm dishes 2 days before transfection. After reaching 90% confluency, cells were transfected by ''nucleofection'' electroporation with 2 mg of the P Bmal1 ::Fluc reporter plasmid in accordance with the manufacturer's protocol (NHDF Nucleofector Kit # VPD-1001, Amaxa Biosystems). After electroporation, cells were grown at 37 C in DMEM + 10% FBS for 1 day. Then, wild-type fibroblasts were treated with forskolin (10 mM) for 2 hr. Knockout fibroblasts were treated with forskolin (10 mM) + 0.1 mM CP-CRY1 + 0.1 mM CP-CRY2 for 2 hr. After this treatment, the medium was replaced with DMEM + 10% FBS including luciferin (0.1 mM) and, in the case of the ''rescue'' samples, also including 0.1 mM CP-CRY1 and 0.1 mM CP-CRY2. The dishes were sealed and luminescence was monitored in an automated luminescence recording apparatus designed for circadian experiments (the ''LumiCycle,'' Actimetrics) at 36 C.
Immunoblotting
Rat-1 cells stably transfected with the P Per2 ::Fluc reporter construct [7] were cultured and synchronized with forskolin as above. Eighteen hours after forskolin synchronization, 50 nM CP-CRY1, 50 nM CP-CRY2, 50 nM CP-CRE, 50 nM CP-mutCRY1, and PBS were added to cells. Every 4 hr after the treatment onset, cells were washed twice with ice-cold PBS and lysed in 100 ml lysis buffer (lysis buffer: 50 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 1% NP40). Lysate proteins were separated by SDS-PAGE (in 10% gels) and then transferred to nitrocellulose membranes for immunoblotting. Primary antibodies were rat anti-mCRY1 monoclonal IgG (from Dr. Aziz Sancar), rabbit anti-mCRY2 IgG (Alpha Diagnostic International), rabbit anti-BMAL1 polyclonal IgG (Oncogene catalog #PC539, lot# D13920-1; see Figure S8 for its characterization), and rabbit anti-CLOCK polyclonal IgG (#233170, Calbiochem). The secondary antibodies were AP-conjugated anti-rabbit IgG (#S3731, Promega) and AP-conjugated anti-rat IgG (Promega, #S3831).
Phase Shift of Fibroblast Oscillations Elicited by CP-CRY Proteins
These experiments used the Rat-1 line that has been stably transfected with a P Per2 ::Fluc reporter construct and that shows a robust circadian rhythm of luciferase activity [7] . The cells were cultured in DMEM (11965-092, GIBCO/Invitrogen) supplemented with 5% FBS, 50 units/ml penicillin, and 50 mg/ml streptomycin in a 5% CO 2 incubator at 37 C. Approximately 5 3 10 5 cells were seeded in a 35 mm dish at least 5 days before the experiment. Three days after the cells reached 100% confluency, the cells were treated with 10 mM forskolin (Sigma) for 2 hr to synchronize the oscillators among the cells in the population. At the end of the forskolin treatment, the medium was replaced with assay medium (DMEM without phenol red, supplemented with bicarbonate [350 mg/L], 5% FBS, 10 mM HEPES [pH 7.2], antibiotics [25 units/ml penicillin and 25 mg/ml streptomycin], and 0.1 mM luciferin [Promega] ). Culture dishes were sealed with a 40 mm microscope glass cover and high-vacuum grease to prevent the evaporation of culture medium. The luminescence rhythm was monitored in the LumiCycle (Actimetrics). For the ''step'' treatments, CP-CRY1 or CP-CRY2, as well as 50 nM of the control proteins CP-CRE and CP-mutCRY1, were added to the cell samples at different phases and left continuously with the cells thereafter while the luminescence patterns were recorded for 5 days or more. Regression analyses to determine period and phase of the luminescence rhythms were performed with the Chrono II program (courtesy of Dr. Till Roenneberg). Rate of damping was assessed with the software included with the Lumicycle (Actimetrics).
Supplemental Data
Additional Experimental Procedures and eight figures are available at http://www.current-biology.com/cgi/content/full/17/13/1091/ DC1/. Damping rates were determined by LUMICYCLE data-analysis software (Actimetrics). The damping rate (d) is the number of days (as 24 hr increments) required for the amplitude of the rhythm to decrease to 1/e (w36.8 %) of the starting value [6] . Values in the table are mean damping rate 6SD for each treatment (n = 4 for experiments 1-3, n = 3 for experiment 4). A two-factor ANOVA analysis revealed that there are not significant differences among the five treatments in any of the four experiments (p value of 0.27), but among the four experiments there are differences in the average damping rate that might be attributable to differences in the condition of the fibroblasts in the various experiments.
